PRQR
ProQR Therapeutics N.V.
NASDAQ · Healthcare · Biotechnology · NL
$2.07
−0.96%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- -$0.11
- Revenue estimate
- $3.9M
Latest reported
- Last report date
- Aug 13, 2026
- EPS actual
- -$0.10
- EPS estimate
- -$0.13
- Revenue actual
- $10.0M
- Revenue estimate
- $4.5M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 6
- EPS misses (12Q)
- 3
- EPS in line (12Q)
- 3
- Avg surprise (4Q)
- +4.3%
- Revenue beats (12Q)
- 3
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $6.75
- PT range
- $3.00 – $10
- Analysts
- 4
4 Buy0 Hold0 Sell
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026